Lantheus Holdings, Inc. (LNTH) Stock Analysis and Metrics

Lantheus Holdings

NASDAQ: LNTH

$104.82 ▲ +1.09 (+1.05%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap6.81 Bn

P/E24.41

P/S4.40

Div. Yield0.00

ROIC (Qtr)0.88

Total Debt (Qtr)570.41 Mn

Revenue Growth (1y) (Qtr)1.23

Add ratio to table…

About

Lantheus Holdings, Inc. is a radiopharmaceutical focused company that enables clinicians to find, fight, and follow disease to improve patient outcomes. The company is headquartered in Massachusetts and maintains offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom.

Lantheus generates revenue primarily from the sale of its radiopharmaceutical products, including PYLARIFY for prostate cancer imaging, DEFINITY for ultrasound enhancement, and Neuraceq for amyloid PET imaging, as well as from licensing agreements, royalties, milestone payments, and contract development and manufacturing organization services provided through its Evergreen subsidiary. The company sells its products throughout the United States to hospitals, independent imaging centers and government facilities, and distributes internationally through direct and third party arrangements in Europe, Canada, Asia Pacific, Latin America and other regions.

The company operates through the following segments: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.

• Radiopharmaceutical Oncology: This segment focuses on PYLARIFY, an FDA approved PET imaging agent that targets prostate specific membrane antigen, and includes related oncology pipeline candidates aimed at detecting and monitoring cancer. The product is distributed through a network of radiopharmacies and is used in PET/CT procedures to detect and monitor metastatic disease.

• Precision Diagnostics: This segment provides DEFINITY, an ultrasound enhancing agent used to improve echocardiogram images, and Neuraceq, a PET imaging agent that binds to beta amyloid plaques in the brain to aid in Alzheimer’s disease assessment. DEFINITY is used in adult and pediatric patients with suboptimal echocardiograms, while Neuraceq supports clinicians in estimating amyloid burden and selecting patients for anti amyloid therapy.

• Strategic Partnerships and Other Revenue: This segment includes biomarker solutions such as MK 6240 and NAV 4694, digital solutions like aBSI and aPROMISE, contract development and manufacturing operations from Evergreen, and licensing agreements that generate royalties and milestone payments from partners such as GE Healthcare. The biomarker programs support clinical trials for Alzheimer’s disease and oncology, while the digital tools provide AI powered image analysis for prostate cancer and bone scans.

Lantheus holds a leading position in the radiopharmaceutical industry, competing with companies such as Telix Pharmaceuticals, Blue Earth Diagnostics (a Bracco subsidiary), GE Healthcare, and Eli Lilly. Its competitive advantages stem from a proprietary product portfolio, a strong patent pipeline, a reliable network of radiopharmacies for production and distribution, and its integrated CDMO capabilities that support both internal programs and external partners. The company also benefits from a diversified revenue base that spans diagnostic imaging, therapeutic development, and contract manufacturing services.

Lantheus serves hospitals, independent imaging centers, and government facilities in the United States, and reaches international markets through distributors in Europe, Canada, Asia Pacific, and other regions. Its products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists. The company also collaborates with academic medical centers and research institutions that utilize its radiopharmaceuticals in clinical studies and development programs.

Investment Thesis

▲ Bull case

Lantheus is strategically positioned to capitalize on the accelerating adoption of Alzheimer's disease-modifying therapies (DMTs), which will drive sustained demand for NEUROCEQ as a companion diagnostic. Management highlighted in Q&A that guidelines increasingly favor earlier diagnostic use in patients with mild cognitive impairment and early Alzheimer's disease, and the company is leveraging its expanded NEUROCEQ PMS footprint—now up to 22 sites—to deepen penetration in existing accounts and unlock incremental growth. This is not merely volume-driven; it reflects a structural shift where NEUROCEQ is becoming integral to treatment eligibility determination for DMTs, with MK-6240 already serving as the imaging agent in 17 pharma-sponsored AD therapeutic programs. The market is underestimating how this diagnostic-therapeutic linkage creates a durable, high-margin growth engine independent of competitive pressures in oncology, especially as DMT approvals expand and reimbursement pathways solidify. With NEUROCEQ revenue growing 14.3% quarter-over-quarter and the company investing in manufacturing expansion to support broader geographic reach, this franchise could deliver multi-year acceleration that current guidance does not fully reflect, particularly as Lantheus avoids discussing pricing strategy but remains focused on ensuring reimbursement clarity for hospital-based customers—a critical enabler for sustained adoption.
The impending launch of PYLARIFY TRUVU in Q4 2026 represents a hidden catalyst that will meaningfully expand Lantheus' addressable market and operational flexibility beyond what current guidance incorporates. Management emphasized that TRUVU’s value lies in larger batch sizes enabled by high-energy cyclotrons, with over 70% of current PYLARIFY supply already produced at sites equipped for this capability. This allows for enhanced supply flexibility—potentially serving more patients per batch or extending delivery to sites further from manufacturing locations—without requiring new capital investment. The company is deliberately sequencing the transition only after securing HCPCS coding and transitional pass-through (TPT) status, ensuring reimbursement readiness before market entry. This meticulous approach minimizes adoption risk and positions TRUVU to capture share from competitors still reliant on lower-yield production methods. While guidance assumes modest volume growth and does not explicitly model TRUVU’s impact until 2027, the seamless transition strategy—where only one product is available per market at a time—eliminates cannibalization risk and preserves pricing discipline. The market is overlooking how this formulation upgrade, combined with a revitalized PMF network investing in higher-energy cyclotrons, could unlock latent capacity and drive stronger-than-expected volume growth in PSMA PET imaging starting in late 2026, setting up a more robust inflection point for 2027 acceleration.
Lantheus’ disciplined capital allocation strategy, particularly its focus on radio diagnostics while evaluating value-maximizing alternatives for radiotherapeutic assets, is creating an underappreciated tailwind to long-term valuation. Management explicitly stated they are allocating capital with discipline, prioritizing radio diagnostics while assessing options for therapeutic assets like PNT2003 and LNTH-2501. The tentative approval of PNT2003 for GEP/NET tumors—offered in March with a PDUFA date extended to June 29, 2026—represents a near-term opportunity that could diversify revenue beyond oncology imaging if successfully launched with proper coding, coverage, and customer preparedness. While management noted these therapeutics are not embedded in 2026 guidance, the company’s deliberate focus on launch readiness—including securing reimbursement pathways—suggests they are de-risking the path to market. The market is ignoring how success here could establish Lantheus as a full-spectrum player in theranostics, leveraging its diagnostic franchise (PYLARIFY/TRUVU) to support therapeutic adoption. This vertical integration potential, coupled with the Evergreen CDMO acquisition boosting strategic partnerships revenue (up 52.1% YoY), is building a more resilient, diversified earnings profile that current EPS guidance of $5–$5.25 fails to fully capture, especially as the company advances its Pharma Solutions pipeline with assets like MK-6240 and Lantheus 2401.

Lantheus is strategically positioned to capitalize on the accelerating adoption of Alzheimer's disease-modifying therapies (DMTs), which will drive sustained demand for NEUROCEQ as a companion diagnostic. Management highlighted in Q&A that guidelines increasingly favor earlier diagnostic use in patients with mild cognitive impairment and early Alzheimer's disease, and the company is leveraging its expanded NEUROCEQ PMS footprint—now up to 22 sites—to deepen penetration in existing accounts and unlock incremental growth. This is not merely volume-driven; it reflects a structural shift where NEUROCEQ is becoming integral to treatment eligibility determination for DMTs, with MK-6240 already serving as the imaging agent in 17 pharma-sponsored AD therapeutic programs. The market is underestimating how this diagnostic-therapeutic linkage creates a durable, high-margin growth engine independent of competitive pressures in oncology, especially as DMT approvals expand and reimbursement pathways solidify. With NEUROCEQ revenue growing 14.3% quarter-over-quarter and the company investing in manufacturing expansion to support broader geographic reach, this franchise could deliver multi-year acceleration that current guidance does not fully reflect, particularly as Lantheus avoids discussing pricing strategy but remains focused on ensuring reimbursement clarity for hospital-based customers—a critical enabler for sustained adoption.
The impending launch of PYLARIFY TRUVU in Q4 2026 represents a hidden catalyst that will meaningfully expand Lantheus' addressable market and operational flexibility beyond what current guidance incorporates. Management emphasized that TRUVU’s value lies in larger batch sizes enabled by high-energy cyclotrons, with over 70% of current PYLARIFY supply already produced at sites equipped for this capability. This allows for enhanced supply flexibility—potentially serving more patients per batch or extending delivery to sites further from manufacturing locations—without requiring new capital investment. The company is deliberately sequencing the transition only after securing HCPCS coding and transitional pass-through (TPT) status, ensuring reimbursement readiness before market entry. This meticulous approach minimizes adoption risk and positions TRUVU to capture share from competitors still reliant on lower-yield production methods. While guidance assumes modest volume growth and does not explicitly model TRUVU’s impact until 2027, the seamless transition strategy—where only one product is available per market at a time—eliminates cannibalization risk and preserves pricing discipline. The market is overlooking how this formulation upgrade, combined with a revitalized PMF network investing in higher-energy cyclotrons, could unlock latent capacity and drive stronger-than-expected volume growth in PSMA PET imaging starting in late 2026, setting up a more robust inflection point for 2027 acceleration.
Lantheus’ disciplined capital allocation strategy, particularly its focus on radio diagnostics while evaluating value-maximizing alternatives for radiotherapeutic assets, is creating an underappreciated tailwind to long-term valuation. Management explicitly stated they are allocating capital with discipline, prioritizing radio diagnostics while assessing options for therapeutic assets like PNT2003 and LNTH-2501. The tentative approval of PNT2003 for GEP/NET tumors—offered in March with a PDUFA date extended to June 29, 2026—represents a near-term opportunity that could diversify revenue beyond oncology imaging if successfully launched with proper coding, coverage, and customer preparedness. While management noted these therapeutics are not embedded in 2026 guidance, the company’s deliberate focus on launch readiness—including securing reimbursement pathways—suggests they are de-risking the path to market. The market is ignoring how success here could establish Lantheus as a full-spectrum player in theranostics, leveraging its diagnostic franchise (PYLARIFY/TRUVU) to support therapeutic adoption. This vertical integration potential, coupled with the Evergreen CDMO acquisition boosting strategic partnerships revenue (up 52.1% YoY), is building a more resilient, diversified earnings profile that current EPS guidance of $5–$5.25 fails to fully capture, especially as the company advances its Pharma Solutions pipeline with assets like MK-6240 and Lantheus 2401.

▼ Bear case

Lantheus faces significant near-term headwinds from evolving competitive dynamics in the PSMA PET market that management is not adequately addressing, despite expressing confidence in its franchise. During Q&A, the CFO acknowledged one competitor is "finding footing with their new products" while another will lose transitional pass-through (TPT) status later in the year—specifically citing October 1 as a timing reference—yet the company offered no concrete data on its own market share trends or competitive positioning beyond vague references to monitoring the marketplace. This evasiveness is concerning because TPT availability is critical for hospital-based customers serving traditional fee-for-service Medicare patients, and any erosion in reimbursement advantage could undermine PYLARIFY’s pricing power and volume growth. The company’s reliance on triangulated market growth estimates—citing lack of clean third-party data sources—further obscures visibility into whether its low-teens PSMA PET market growth assumption for 2026 is realistic amid intensifying competition. With PYLARIFY revenue declining 6.5% YoY in Q1 despite overall portfolio growth, the market may be ignoring how competitive pressures are already offsetting tailwinds from TRUVU readiness, potentially delaying or diminishing the expected benefits of the formulation transition.
The NEUROCEQ franchise, while showing strong quarterly growth, is vulnerable to a potential slowdown in Alzheimer’s DMT adoption and reimbursement uncertainty that management did not sufficiently qualify. Although Amanda Morgan highlighted broader adoption of Alzheimer’s DMTs and clinical guidelines favoring earlier diagnostic use, she offered no specifics on attach rates to specific therapies or how changes in coverage policies—such as Medicare’s recent limited coverage with evidence development (CED) for amyloid-targeting therapies—could impact NEUROCEQ utilization. The company’s emphasis on expanding its PMS footprint to 22 sites and leveraging portfolio relationships assumes continued therapeutic momentum, but if DMT rollout faces delays due to safety concerns, pricing pressures, or restrictive payer policies, the diagnostic demand could falter. Management’s avoidance of discussing pricing strategy for NEUROCEQ, combined with their refusal to provide specific market share figures, raises questions about whether they are downplaying sensitivity to reimbursement shifts. With NEUROCEQ contributing only $35.4 million in Q1 revenue, the market may be overestimating its ability to offset weakness in core franchises if the Alzheimer’s therapeutic landscape does not evolve as optimistically anticipated.
Lantheus’ capital allocation priorities and ongoing CEO transition pose execution risks that could delay or dilute the expected growth acceleration in 2027, a risk the market is underpricing. Management repeatedly cited the imminent CEO change as a reason for maintaining current guidance, with the CFO stating they want to "allow that person to own the balance of the year," suggesting strategic decisions—including resource allocation for TRUVU launch, PNT2003 commercialization, and pipeline investments—may be deferred until a permanent leader is in place. This creates a potential vacuum in strategic momentum during a critical period when regulatory milestones (e.g., PYLARIFY TRUVU conversion in Q4, PNT2003 approval by June 29) and commercial readiness efforts are underway. Furthermore, while the company emphasizes disciplined capital deployment, its evaluation of "value-maximizing alternatives for radiotherapeutic assets" introduces uncertainty about whether it will divest or underinvest in promising pipeline candidates like PNT2003 or LNTH-2501, potentially sacrificing long-term diversification for short-term financial engineering. The market is ignoring how this leadership transition and strategic ambiguity could disrupt the seamless execution needed for TRUVU’s launch readiness—particularly the coordination required with PMF partners on manufacturing site approvals and reimbursement coding—thereby pushing back the anticipated 2027 inflection point and undermining confidence in the company’s ability to deliver on its long-term roadmap.

Lantheus faces significant near-term headwinds from evolving competitive dynamics in the PSMA PET market that management is not adequately addressing, despite expressing confidence in its franchise. During Q&A, the CFO acknowledged one competitor is "finding footing with their new products" while another will lose transitional pass-through (TPT) status later in the year—specifically citing October 1 as a timing reference—yet the company offered no concrete data on its own market share trends or competitive positioning beyond vague references to monitoring the marketplace. This evasiveness is concerning because TPT availability is critical for hospital-based customers serving traditional fee-for-service Medicare patients, and any erosion in reimbursement advantage could undermine PYLARIFY’s pricing power and volume growth. The company’s reliance on triangulated market growth estimates—citing lack of clean third-party data sources—further obscures visibility into whether its low-teens PSMA PET market growth assumption for 2026 is realistic amid intensifying competition. With PYLARIFY revenue declining 6.5% YoY in Q1 despite overall portfolio growth, the market may be ignoring how competitive pressures are already offsetting tailwinds from TRUVU readiness, potentially delaying or diminishing the expected benefits of the formulation transition.
The NEUROCEQ franchise, while showing strong quarterly growth, is vulnerable to a potential slowdown in Alzheimer’s DMT adoption and reimbursement uncertainty that management did not sufficiently qualify. Although Amanda Morgan highlighted broader adoption of Alzheimer’s DMTs and clinical guidelines favoring earlier diagnostic use, she offered no specifics on attach rates to specific therapies or how changes in coverage policies—such as Medicare’s recent limited coverage with evidence development (CED) for amyloid-targeting therapies—could impact NEUROCEQ utilization. The company’s emphasis on expanding its PMS footprint to 22 sites and leveraging portfolio relationships assumes continued therapeutic momentum, but if DMT rollout faces delays due to safety concerns, pricing pressures, or restrictive payer policies, the diagnostic demand could falter. Management’s avoidance of discussing pricing strategy for NEUROCEQ, combined with their refusal to provide specific market share figures, raises questions about whether they are downplaying sensitivity to reimbursement shifts. With NEUROCEQ contributing only $35.4 million in Q1 revenue, the market may be overestimating its ability to offset weakness in core franchises if the Alzheimer’s therapeutic landscape does not evolve as optimistically anticipated.
Lantheus’ capital allocation priorities and ongoing CEO transition pose execution risks that could delay or dilute the expected growth acceleration in 2027, a risk the market is underpricing. Management repeatedly cited the imminent CEO change as a reason for maintaining current guidance, with the CFO stating they want to "allow that person to own the balance of the year," suggesting strategic decisions—including resource allocation for TRUVU launch, PNT2003 commercialization, and pipeline investments—may be deferred until a permanent leader is in place. This creates a potential vacuum in strategic momentum during a critical period when regulatory milestones (e.g., PYLARIFY TRUVU conversion in Q4, PNT2003 approval by June 29) and commercial readiness efforts are underway. Furthermore, while the company emphasizes disciplined capital deployment, its evaluation of "value-maximizing alternatives for radiotherapeutic assets" introduces uncertainty about whether it will divest or underinvest in promising pipeline candidates like PNT2003 or LNTH-2501, potentially sacrificing long-term diversification for short-term financial engineering. The market is ignoring how this leadership transition and strategic ambiguity could disrupt the seamless execution needed for TRUVU’s launch readiness—particularly the coordination required with PMF partners on manufacturing site approvals and reimbursement coding—thereby pushing back the anticipated 2027 inflection point and undermining confidence in the company’s ability to deliver on its long-term roadmap.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password